Lv41
540 积分 2022-02-06 加入
Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers
1个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
1个月前
已完结
Colorectal cancer
1个月前
已完结
Gastric cancer
1个月前
已完结
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors
2个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
5个月前
已完结
Engineering IL-2 for immunotherapy of autoimmunity and cancer
5个月前
已完结
Biology and regulation of IL-2: from molecular mechanisms to human therapy
5个月前
已完结
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies
5个月前
已完结
皖公网安备34019202002308
